Carter's, Inc.

NYSE:CRI Stock Report

Mkt Cap: US$2.4b

We’ve recently updated our valuation analysis.

Carter's Valuation

Is CRI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRI?

Other financial metrics that can be useful for relative valuation.

CRI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA8.1x
PEG Ratio2.6x

Price to Earnings Ratio vs Peers

How does CRI's PE Ratio compare to its peers?

The above table shows the PE ratio for CRI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average20.7x
KTB Kontoor Brands
9.8x3.7%US$2.3b
ZGN Ermenegildo Zegna
54.4x25.7%US$3.0b
UAA Under Armour
9x-0.2%US$3.3b
OXM Oxford Industries
9.5x6.1%US$1.6b
CRI Carter's
11.1x4.4%US$2.4b

Price-To-Earnings vs Peers: CRI is good value based on its Price-To-Earnings Ratio (11.1x) compared to the peer average (20.7x).

Price to Earnings Ratio vs Industry

How does CRI's PE Ratio compare vs other companies in the US Luxury Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.9%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.9%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: CRI is good value based on its Price-To-Earnings Ratio (11.1x) compared to the US Luxury industry average (11.2x)

Price to Earnings Ratio vs Fair Ratio

What is CRI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.1x
Fair PE Ratio10.3x

Price-To-Earnings vs Fair Ratio: CRI is expensive based on its Price-To-Earnings Ratio (11.1x) compared to the estimated Fair Price-To-Earnings Ratio (10.3x).

Share Price vs Fair Value

What is the Fair Price of CRI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRI ($63.27) is trading above our estimate of fair value ($55.03)

Significantly Below Fair Value: CRI is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$62.67
US$68.29
+9.0%
11.0%US$84.00US$60.00n/a7
May ’24US$67.87
US$68.57
+1.0%
10.5%US$84.00US$62.00n/a7
Apr ’24US$71.92
US$68.57
-4.7%
10.5%US$84.00US$62.00n/a7
Mar ’24US$75.36
US$69.86
-7.3%
10.4%US$84.00US$62.00n/a7
Feb ’24US$84.97
US$70.71
-16.8%
11.0%US$84.00US$62.00n/a7
Jan ’24US$74.61
US$71.29
-4.5%
11.4%US$84.00US$62.00n/a7
Dec ’23US$73.07
US$71.29
-2.4%
11.4%US$84.00US$62.00n/a7
Nov ’23US$66.93
US$73.57
+9.9%
17.0%US$100.00US$62.00n/a7
Oct ’23US$65.53
US$80.00
+22.1%
15.0%US$100.00US$62.00n/a7
Sep ’23US$73.50
US$80.00
+8.8%
15.0%US$100.00US$62.00n/a7
Aug ’23US$83.25
US$85.63
+2.9%
19.1%US$120.00US$68.00n/a8
Jul ’23US$70.80
US$99.25
+40.2%
19.6%US$121.00US$68.00n/a8
Jun ’23US$76.50
US$104.33
+36.4%
22.4%US$145.00US$68.00US$61.489
May ’23US$84.24
US$113.33
+34.5%
15.7%US$145.00US$82.00US$67.879
Apr ’23US$89.21
US$119.22
+33.6%
9.4%US$145.00US$105.00US$71.929
Mar ’23US$97.06
US$118.67
+22.3%
9.4%US$145.00US$105.00US$75.369
Feb ’23US$93.04
US$117.89
+26.7%
10.2%US$145.00US$101.00US$84.979
Jan ’23US$101.22
US$118.89
+17.5%
10.4%US$145.00US$101.00US$74.619
Dec ’22US$98.65
US$118.89
+20.5%
10.4%US$145.00US$101.00US$73.079
Nov ’22US$102.00
US$118.11
+15.8%
9.2%US$138.00US$101.00US$66.939
Oct ’22US$99.49
US$120.75
+21.4%
7.6%US$138.00US$105.00US$65.538
Sep ’22US$102.96
US$120.75
+17.3%
7.6%US$138.00US$105.00US$73.508
Aug ’22US$97.74
US$119.75
+22.5%
6.5%US$131.00US$105.00US$83.258
Jul ’22US$104.85
US$119.75
+14.2%
6.5%US$131.00US$105.00US$70.808
Jun ’22US$102.33
US$119.75
+17.0%
6.5%US$131.00US$105.00US$76.508

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies